4DMedical (ASX:4DX) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)


ASX:4DX 4DMedical Ltd ASX:4DX
64 GF Score
Price A$4.16
GF Value A$1.44
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is 4DMedical ROE % Adjusted to Book Value?

4DMedical ASX:4DX -8.97% 64 ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus rates ASX:4DX with a GF Score™ of 64/100 and a GF Value™ of A$1.44 (Significantly Overvalued). The stock has 2 warning signs investors should review.

4DMedical's ROE % for the quarter that ended in Dec. 2025 was -1,720.66%. 4DMedical's PB Ratio for the quarter that ended in Dec. 2025 was N/A. 4DMedical's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was N/A.

4DMedical ROE % Adjusted to Book Value Related Terms

4DMedical ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for 4DMedical's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4DMedical ROE % Adjusted to Book Value Chart

4DMedical Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -19.63 -16.63 -15.17 -16.41 -25.57

4DMedical Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.26 -16.70 -17.71 -20.20 0.00

ASX:4DX vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, 4DMedical's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4DMedical ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, 4DMedical's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where 4DMedical's ROE % Adjusted to Book Value falls into.


ASX:4DX
64GF Score
4DMedical Ltd ASX:4DX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4DMedical ROE % Adjusted to Book Value Calculation

4DMedical's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-44.49% / 1.74
=-25.57%

4DMedical's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-1,720.66% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
4DMedical (ASX:4DX) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on 4DMedical and its competitors.
Is 4DMedical's ROE % Adjusted to Book Value too high?
4DMedical's current ROE % Adjusted to Book Value is 0.00%. Overall, 4DMedical has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's ROE % Adjusted to Book Value compare to ABT and SYK?
4DMedical's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on 4DMedical and its competitors. 4DMedical's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (ASX:4DX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$1.44, compared to a current price of A$4.16 — trading 188.9% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. 4DMedical's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For 4DMedical (ASX:4DX), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4DMedical (ASX:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued. The current stock price of A$4.16 is trading 188.9% above its estimated GF Value™ of A$1.44. GuruFocus considers 4DMedical to be Significantly Overvalued.

Key valuation signals for ASX:4DX:

  • ROE % Adjusted to Book Value: 0.00%
  • GF Value™: A$1.44 vs. price of A$4.16 (188.9% above fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ASX:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4DMedical Business Description

Other Exchanges FDMDF:USAMQ7:Germany
Address 700 Swanston Street, Level 7, Melbourne Connect, Carlton, VIC, AUS, 3053
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
64GF Score

Get the complete analysis for ASX:4DX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$4.16
Price
A$1.44
GF Value